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INTRODUCTION
Cardiac complications are the leading
cause of morbidity and mortality in indi-
viduals with diabetes mellitus (DM). DM
increases the risk of morbid events in 
individuals with coronary artery disease
(CAD), hypertension (HTN), hypercho-
lesterolemia, and postmyocardial infarc-
tion (MI) (1,2). Moreover, DM can lead to
cardiac dysfunction, microvascular im-
pairment, structural remodeling and
eventually heart failure (HF) in the ab-
sence of a known underlying pathology
(for example, CAD or HTN) (3,4). The
pathophysiology of diabetic cardiomy-
opathy has been reviewed recently (3,5,6).
Thyroid hormones (THs) are important
regulators of the cardiovascular system
and peripheral vasculature (7,8). THs in-
fluence myocardial contractility, total pe-
ripheral resistance and ultimately cardiac
output (7,8). Overt and subclinical hy-
pothyroidism are associated with cardio-
vascular dysfunction including impaired
contractility and decreased cardiac out-
put, increased peripheral vascular resist-
ance, impaired coronary blood flow and
relaxation abnormalities, which results in
an increased clinical risk for all-cause and
cardiovascular mortality (9–12).
In rodent models, we demonstrated
previously that chronic hypothyroidism
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by itself can lead to dilated HF character-
ized by severe left ventricular (LV) dys-
function, microvascular impairment, and
maladaptive chamber remodeling
(13,14). In addition, MI, pressure over-
load, pathological hypertrophy and HF
have been shown to cause local cardiac
tissue hypothyroidism by augmenting
the expression and activity of cardiac TH
hormone-degrading enzymes (15–18).
DM patients have a higher frequency
of clinical and subclinical hypothy-
roidism than non-DM individuals
(19–21), which is a likely contributor to
increased cardiovascular risk and poor
outcomes in this population (22). DM and
hypothyroidism produce similar negative
effects on cardiac function and are associ-
ated with impaired contractility (3,7,8,23),
α to β myosin heavy chain (MHC) iso-
form shift (7,8,13,24), microvessel/blood
flow abnormalities (4,13,25–27), and dys-
regulation of Ca2+ handling (23,28–31).
Cumulatively, these observations suggest
that individuals with DM are at increased
risk for cardiac dysfunction associated
with both systemic and/or local thyroid
hormone imbalance.
A study by Davidson et al. showed im-
proved heart function with T3 treatment of
STZ-SHR rats (32). However, induction of
diabetes in SHR resulted in severe body
mass reduction and worsening cachexia
from the administered T3 dose. While en-
couraging, the potential benefits from a
therapeutic dose of T3 in DM with stable
body mass has not been determined. In
addition, the relationship between DM
and cardiac tissue hypothyroidism has not
been explored in great depth. Although
low tissue TH levels have been speculated
in the setting of diabetes, to our knowl-
edge, this observation has never been con-
firmed. If, in fact, DM leads to low tissue
TH levels, restoration of TH homeostasis
by physiologic TH supplementation is
likely to help attenuate and/or reverse
cardiac dysfunction in this high risk popu-
lation. In the current investigation, we
show that chronic DM, without superim-
posed pathological cardiac stimuli, can
lead to local cardiac tissue hypothy-
roidism irrespective of serum TH levels.
Our results demonstrate the important re-
lationship between local TH dysfunction
and cardiac dysfunction in DM hearts.
MATERIALS AND METHODS
Detailed materials and methods are
available in the Supplemental Data.
Animal Model and Experimental
Design
Five-month-old female SD rats were ob-
tained from Harlan (Indianapolis, IN,
USA). To replicate a mild, noninsulin-
 dependent diabetic phenotype, nicoti-
namide (N; 200 mg/kg) pretreatment was
given prior to streptozotocin (STZ; 
65 mg/kg). Eight days after STZ/N, fast-
ing blood glucose (BG) was used to con-
firm DM (Supplementary Figure 1; control:
6.5 mmol/L; STZ/N: 14.1 mmol/L). One
month after STZ/N injections, diabetic
rats were randomly assigned to one of the
following groups (N = 10/group): STZ/N
or STZ/N + 0.03 μg/mL T3 (STZ/N-T3);
Age matched rats receiving vehicle injec-
tions only served as nondiabetic controls
(control; C). T3 was administered noninva-
sively as solution (T3: ethanol/ glycerol)
dissolved in drinking water (final concen-
tration in water: 0.03 μg/mL T3). After
2 months of T3 treatment (3 months post-
DM induction), terminal cardiac function
was assessed by echocardiography and LV
hemodynamics. All animals were kept on
a 12-h light–dark cycle and food and
water were provided ad libitum. All ex-
periments and protocols were performed
in accordance with the Guide for the Care
and Use of Laboratory Animals (33), and ap-
proved by the University of South Dakota
Animal Care and Use Committee.
Measurement of Serum TH and
Cardiac TH Levels and of Blood
Glucose
Serum TH levels were measured using
commercial enzyme-linked immunosor-
bent assay (ELISA) kits (TSH: ALPCO,
Salem, NH, USA; T3, FT3, T4, FT4:
Monobind, Lake Forest, CA, USA) ac-
cording to manufacturer specifications.
Cardiac TH extracts from pooled LV tis-
sues homogenates were measured using
tandem HPLC-mass spectrometry as de-
scribed previously (15). Blood glucose
(BG) levels were measured using an As-
censia Contour blood glucose meter
(Bayer, Pittsburgh, PA, USA).
Real-Time PCR
Gene expression was evaluated using
commercially available primers (SABio-
sciences, Qiagen Inc., Valencia, CA, USA)
for deiodinase induction pathways, car-
diac genes, TH transporters, cytosolic 
TH-binding proteins, vascular growth
regulators, LV collagen and custom gen-
erated primers for DIO3 deiodinase
(Sigma-Aldrich, St. Louis, MO, USA)
(Supplementary Table 1). Gene expres-
sion was normalized using housekeeping
genes cyclophilin A and Rplp1.
Immunohistochemistry and
Immunofluorescence
Formalin-fixed, paraffin-embedded tis-
sue sections from the middle of the LV
(5-7 μm) were used to evaluate changes
in LV terminal resistance arterioles, capil-
laries, LV fibrosis, and DIO3 expression.
Arteriole and capillary staining. FITC-
Isolectin-B4 (IB4; Vector, Burlingame, CA,
USA) and Cy3-α-smooth muscle actin 
(α-SMA; Sigma-Aldrich) were used in
combination to label endothelial cells and
vascular smooth muscle cells respectively.
Arteriolar numeric density (ND), arterio-
lar length density (LD), capillary ND
density, and total capillary length were
quantified using previously described
methods (34,35).
LV DIO3 deiodinase staining. LV tis-
sue sections were stained using a com-
mercially available IHC/DAB detection
kit (Epitomics, Burlingame, CA, USA)
and a previously validated rabbit anti-
DIO3 antibody (36–38) (Novus, Littleton,
CO, USA). Specificity was confirmed
using an equivalent concentration of rab-
bit IgG in place of primary antibody
(Supplementary Figure 2).
Myocardial fibrosis. LV tissue sections
were stained with Masson trichrome for
visualization of myocardial fibrosis. Values
are represented as the proportion of colla-
gen normalized to the total tissue area.
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Data Analysis
All data are expressed as means (SD),
unless otherwise noted. Statistical analysis
was performed by paired Student t test
(pre- versus post-BW), one-way analysis
of variance (ANOVA) followed by Holm-
Sidak post hoc analysis, or nonparametric
one-way ANOVA (Kruskal-Wallis) ranked
measurements with Dunn post hoc analy-
sis. Logarithmic transformations were
performed when necessary. Statistical
analysis was performed using SigmaPlot 11
(Systat Software, San Jose, CA, USA).
Gene expression was analyzed by the
ΔΔCt method using online software from
SABiosciences. Values of p < 0.05 were
considered statistically significant.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Physical Data
The effectiveness of the STZ/N treat-
ment was confirmed by the two-fold in-
crease in serum glucose levels versus
control (C, STZ/N, STZ/N-T3: 13, 26,
24 mmol/L, respectively). Changes in
body weight, LV weight and heart weight
in the STZ/N- and STZ/N-T3-treated ani-
mals were similar to the control group
over the course of the study (Supplemen-
tary Table 2). Notably, Nicotinamide pre-
treatment prevented any reduction in
body weight and heart weight commonly
observed with STZ treatment alone (39).
Furthermore, the T3 dose used to treat the
STZ animals had no effect on body tem-
perature, heart rate or blood pressure
measurements (Supplementary Table 2).
Diabetic Hearts Have Reduced
Cardiac Tissue TH Levels despite
Normal Serum TH Levels
Terminal TH concentrations in serum
and cardiac tissue are shown in Figure 1
and Supplementary Figure 3. STZ/N was
not associated with changes in serum T4,
T3, FT3 or FT4 levels; however, TSH val-
ues were two-fold higher compared with
control. Notably, the T3 dose used to treat
the STZ/N animals caused a significant
reduction in serum TSH levels despite
the lack of increase in serum T3, FT3 or
suppression of serum T4 or FT4.
In contrast to the normal serum TH
levels in STZ/N animals, cardiac tissue
T3 and T4 content was reduced substan-
tially (39% and 17% reduction, respec-
tively), indicating a 33% decrease in the
T3:T4 ratio (Figure 1D–F). The apparent
physiologic replacement dosage of T3 ap-
peared to prevent the decline in cardiac
tissue T3 levels and normalized the T3:T4
ratio without elevating serum TH levels
or producing overt signs of hyperthy-
roidism (Supplementary Table 2).
T3 Treatment Attenuates DM-Induced
Hemodynamic Dysfunction and
Significantly Improves Cardiac
Relaxation
Hemodynamic data are summarized in
Figure 2 and Supplementary Table 2.
STZ/N did not produce a significant ef-
fect on LV systolic pressure or heart rate.
However, STZ/N led to cardiac dysfunc-
tion as evidenced by significant reduc-
tions in the maximal rate of pressure de-
velopment (dP/dT Max; 36% reduction
versus C, p < 0.01) and maximal rate of
pressure decline (dP/dT Min; 41% reduc-
tion versus C, p < 0.01), with a signifi-
cantly increased time constant of isovolu-
mic relaxation (tau; 72% increase versus
C, p < 0.01). T3 treatment of the STZ/N
animals normalized measurements of
contractile function including dP/dT
Max, dP/dT Min and tau. These findings
may be explained by an enhancement of
the β adrenergic system as evidenced by
the tendency for increased β1 adrenergic
receptor expression in TH-treated hearts
(Supplementary Figure 4).
DM Is Associated with Adverse
Cardiac Chamber Remodeling Which
Is Attenuated by T3 Treatment
Echocardiographic data are summa-
rized in Table 1. STZ/N-treated rats had
Figure 1. Serum and tissue THs. (A) Serum FT3, free triiodothyronine in serum. (B) Serum FT4,
free thyroxine in serum. (C) TSH, thyroid stimulating hormone in serum. (D) Cardiac T3, tri-
iodothyronine in cardiac tissue. (E) Cardiac T4, thyroxine in cardiac tissue. (F) Cardiac T3:T4
ratio, ratio of intracardiac T3 to T4. Values represented as means (SD) for groups with ≥3
samples and means (raw values) for groups with two samples; n = 2–3 pooled samples/
group for D–F. Each pooled LV sample within an experimental group consisted of pooled
LV tissue from 2 to 4 hearts (6 to 8 hearts/group); †p < 0.05 versus STZ/N. Statistical analysis
was only performed on A–C.
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significantly increased LV chamber inter-
nal diameter (LVID; p < 0.01) in systole,
while anterior (AW; p < 0.01) and poste-
rior (LVPW; p < 0.01) wall thickness was
decreased in systole. This adverse re-
modeling was associated with an eleva-
tion in the anatomical parameters of sys-
tolic wall stress as indicated by a 39%
increase in LVID/LVPW ratio when com-
pared with controls. T3 treatment tended
to cause normalization of these STZ/N-
induced changes in systolic parameters.
Loss of Small Arteriolar Resistance
Vessels in the Diabetic Myocardium Is
Prevented with T3 Treatment
Arteriolar and capillary morphometric
analysis is shown immunohistologically
in Figures 3A, B and quantified in Fig-
ures 3C–E. Arteriolar numeric (ND) and
length density (LD) were reduced signifi-
cantly by ~25% in the STZ/N group
compared with control (Figures 3C, D).
The majority of this reduction came from
losses in the smallest arterioles (<15 μm).
Diabetic rats treated with T3 had arterio-
lar ND and LD values almost identical to
nondiabetic controls. No differences
were observed in total capillary density
or total capillary length among groups
(Figure 3E). Gene expression analysis of
potential T3 responsive vascular growth
regulators is shown in Figure 3F. STZ/N
led to significant reductions in thyroid
receptor β (TR-β, p < 0.01) and vascular
growth modulators including vascular
endothelial growth factor A (VEGF-A, p <
0.05), and endothelial nitric oxide syn-
thase (eNOS, p < 0.05), and significant el-
evations in smoothened homolog (SMO,
p < 0.01) and midkine (MdK, p < 0.05). 
T3 treatment tended to normalize vascu-
lar growth factor expression.
DM is Associated with Reexpression of
Fetal Genes in Cardiac Tissue
Protein and gene expression analyses of
fetal genes are summarized in Figure 4 and
Supplementary Figure 5. Untreated DM
hearts showed reexpression of the fetal
gene phenotype typically observed during
cardiac hypertrophy, heart failure and tis-
sue hypothyroidism (7,39). The myosin
heavy chain (MHC) isoform changes ob-
served in the STZ/N hearts were similar
to those observed in hypothyroidism, and
this was normalized with T3 treatment
(Figure 4A). Protein analysis confirmed
these MHC isoform gene expression
changes (Figure 4B). The STZ/N-induced
reduction in sarcoplasmic/endoplasmic
reticulum calcium ATPase 2 (SERCA2a)
protein and upregulation of PLB were re-
versed by T3 treatment (Figures 4C, D).
Notably, Ser16 phosphorylation of PLB
was increased (p = 0.08) with T3 treatment
which, when expressed as a fraction of
total PLB protein, indicates a reduced in-
hibitory effect of PLB on SERCA2a activ-
ity, which may explain the observed posi-
tive effect of T3 treatment on cardiac
contractile function.
Deiodinase Expression in Diabetic
Hearts
To explain the reduction in myocardial
tissue content of T3, LV tissue sections
were evaluated for the presence of DIO3
Figure 2. T3 treatment attenuates DM-induced hemodynamic dysfunction and signifi-
cantly improves parameters of cardiac relaxation. Values are means (SD). (A) HR, heart
rate. (B) LVSP, LV systolic pressure. (C) LVEDP, LV end-diastolic pressure. (D) Tau, time con-
stant of LV isovolumic relaxation. (E) dP/dT Max, maximal rate of pressure development.
(F) dP/dT, Maximal rate of pressure decline. n, Number of animals per group. *p < 0.05
versus control; †p < 0.05 versus STZ/N.
Table 1. LV echocardiography.a
Control STZ/N STZ/N-T3
nb 10 10 10
LVIDdc (mm) 7.39 (0.4) 7.93 (0.8) 7.96 (0.7)
AWd (mm)d 1.33 (0.1) 1.28 (0.2) 1.25 (0.1)
LVPWd (mm)e 1.36 (0.1) 1.31 (0.2) 1.29 (0.1)
LVIDs (mm)c 4.19 (0.5) 5.10 (0.8)f 4.80 (0.8)
AWs (mm)d 2.46 (0.2) 2.15 (0.2)f 2.34 (0.3)
LVPWs (mm)e 2.47 (0.1) 2.21 (0.2)f 2.35 (0.2)
LVIDs/LVPWsg 1.72 (0.3) 2.38 (0.4)f 2.10 (0.5)
aValues are means (SD).
bn, Number per group.
cLVID, LV internal diameter in diastole (d) and systole (s).
dAW, anterior wall thickness in diastole (d) and systole (s).
eLVPW, LV posterior wall thickness in diastole (d) and systole (s).
fp < 0.05 versus control.
gLVID/LVPW, ratio of LV internal diameter to posterior wall thickness in systole.
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deiodinase by immunostaining and
mRNA expression (Figure 5). Robust
DIO3 protein expression was observed in
untreated STZ/N hearts while the control
and T3-treated hearts had low expression.
DIO3 staining was observed in cardiac
myocytes throughout the myocardium
distributed in a heterogeneous manner
similar to the pattern reported in post-MI
rodents (15). To explore the role of cardiac
deiodinase expression further, DIO1,
DIO2 and DIO3 deiodinase mRNA ex-
pressions were evaluated. Both untreated
and T3-treated diabetic hearts had a non-
significant trend toward decreased DIO2
mRNA expression. Interestingly, only un-
treated diabetic hearts showed a tendency
toward increased DIO3 mRNA expres-
sion. DIO3 deiodinase is the primary en-
zyme responsible for intracellular break-
down and inactivation of both T4 (T4 to
rT3) and T3 (T3 to T2) (41). This increased
expression in untreated diabetic hearts
may be responsible for the observed re-
ductions in cardiac TH levels. Similarly,
only untreated diabetic hearts showed a
trend for increased DIO1 expression, al-
though with variability (data not shown).
LV Collagen Expression
While significant collagen accumula-
tion does not appear to be present at this
early time point, STZ/N was associated
with a 25% higher collagen content com-
pared with control (1.27% versus 1.02%)
and a 37% higher collagen content com-
pared with STZ/N-T3 (1.27% versus
0.93%). Untreated diabetic rats had sig-
nificant increases in the gene expression
of transforming growth factor (TGF)β1
and TGFβ2. Treated and untreated dia-
betic rats had similar gene expression of
collagen 1, collagen 3, lysyl oxidase and
TGFβ3 (Supplementary Figure 7).
Expression of TH Transporters and
Cytosolic TH-Binding Proteins in the
Myocardium
To determine whether TH uptake into
the myocardium might be reduced in di-
abetic hearts, we analyzed expression of
known TH transporters (monocarboxy-
late transporter [MCT], solute carrier
Figure 3. Loss of small arteriolar resistance vessels in the diabetic myocardium is prevented
with T3 treatment. Values represent means (SD). (A) Representative images of small arteriolar
resistance vessels used for arteriolar numeric (ND) and length density (LD) quantification
(scale bar = 50 μm). (B) Representative images of myocardial capillaries used for capillary
numeric density and length quantification (scale bar = 20 μm). (C) Arteriolar ND, arteriolar nu-
meric density quantification. (D) Arteriolar LD, arteriolar length density quantification. (E) Cap-
illary ND & Length, capillary numeric density and length quantification. Arteriolar ND, arterio-
lar LD, capillary ND, capillary length were calculated using previously described methods
(34). (F) Absolute gene expression of cardiac regulators of vascular function. n = 5–8/group;
IB4, Isolectin-B4; α-SMA, α-smooth muscle actin; TR-β, thyroid receptor β; VEGF-A, vascular en-
dothelial growth factor A; eNOS, endothelial nitric oxide synthase; bFGF; basic fibroblast
growth factor; MdK, midkine; HIF1α, hypoxia inducible factor 1-α; SMO, smoothened homolog
(Drosophila); Angpt2, angiopoietin-2; *p < 0.05 versus control; †p < 0.05 versus STZ/N.
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transporter family [SLC], solute carrier
organic anion transporter family [SLCO],
fatty acid translocase [FAT], large neutral
amino acid transporter [LAT]) (Figure 6).
The increased expression of the majority
of TH transporters in the STZ/N rats
was consistent with cardiac tissue hy-
pothyroidism (35). T3 treatment tended
to normalize mRNA expression of most
TH transporters. The expression of sev-
eral known cytosolic TH-binding pro-
teins was decreased in diabetic hearts
and T3 treatment tended to reverse this
effect (Supplementary Figure 8).
DISCUSSION
This study evaluated the relationship
between cardiac tissue hypothyroidism
and cardiac dysfunction in the setting of
DM. In addition, we sought to establish
the efficacy and safety of low-dose T3 re-
placement as a potential adjunct therapy
to attenuate and/or reverse early cardiac
dysfunction in diabetic hearts. Very little
is known regarding the influence of low
thyroid function in the setting of DM-
 induced cardiac dysfunction. It has been
hypothesized that decreased TH levels
and/or TH signaling could play a pro-
tective role during cardiac pathology by
reducing cardiac metabolism. Con-
versely, there is mounting evidence sup-
porting the notion that cardiac tissue
(myocardial) TH dysfunction is a com-
mon and deleterious feature of many dis-
ease states and cardiac pathologies
(9,15–18). In accordance, we propose that
low cardiac tissue TH levels represent a
deleterious manifestation of tissue spe-
cific endocrine imbalance and restoration
of tissue TH homeostasis is a logical and
beneficial treatment option.
In the current study, DM led to cardiac
fetal gene reexpression, contractile dys-
function, relaxation/diastolic abnormali-
ties and microvascular remodeling.
These responses appear to be present
during the early stages of diabetic car-
diac dysfunction and occur before signs
of cardiac hypertrophy, LV dilation and
fibrosis and systolic impairment as have
been reported previously (3,4,29). Initia-
tion of T3 treatment during this early pe-
riod of dysfunction preserves cardiac
function and prevents the loss of the ar-
teriolar resistance vessel network. Impor-
tantly, this investigation demonstrates
that physiologic T3 replacement can be
safely administered over a long period of
time and can positively influence the dia-
betic heart without causing symptoms of
hyperthyroidism or elevating serum T3
and T4 levels. Since T3 treatment of
STZ/N rats led to no changes in heart
mass, body mass, body temperature,
heart rate or blood pressure, it appears
that the observed improvements oc-
curred without significantly affecting
metabolism.
Although it is well established that
DM patients have a high frequency of
clinical or subclinical hypothyroidism
(19,20,22), the breadth and importance of
cardiac tissue thyroid dysfunction is cur-
rently unknown. To our knowledge, this
is the first investigation to show that DM
alone, without concomitant pathological
stimuli such as hypertension or myocar-
dial infarction may lead to cardiac tissue
hypothyroidism (see Figure 1). We also
confirm that serum TH levels did not re-
flect the observed cardiac tissue hy-
pothyroidism (normal THs in serum, re-
duced THs in cardiac tissue) in the
setting of DM. Recently, our lab has pub-
lished that in models of subclinical hy-
pothyroidism, serum T3 and T4 levels can
be within normal limits even when car-
diac tissue T3 levels and LV function are
significantly depressed (35,42). Findings
from the current investigation support
Figure 4. Diabetes leads to reexpression of fetal genes in adult cardiac tissue. (A) MHC iso-
form mRNA distribution shown as % of total MHC mRNAs as measured by qPCR. (B) Protein
expression of β-MHC isoform and total MHC detected by Western blot. Expression repre-
sented as ratio of β-MHC to total MHC expression. (C) Cardiac protein expression of sar-
coplasmic reticulum proteins detected by Western blot. (D) Quantitative summary of nor-
malized protein expression. MHC, myosin heavy chain; SERCA2a, sarcoplasmic/endoplasmic
reticulum calcium ATPase 2; PLB, phospholamban; p-PLB, phosphorylated phospholamban
(site of phosphorylation); n = 4–8/group. *p < 0.05 versus control; †p < 0.05 versus STZ/N.
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and extend these observations to the set-
ting of DM. Clinical detection of subclini-
cal thyroid dysfunction in the diabetic
population is further complicated by sev-
eral widely used antidiabetic drugs (for
example, Metformin) which are known
to artificially suppress serum TSH levels
(43). Consequently, it appears that clini-
cal assessment of serum TH levels alone
is insufficient to accurately predict car-
diac tissue TH levels and dysfunction in
diabetic hearts with borderline hypothy-
roid conditions.
Myocardial TH inactivation by induc-
tion of DIO3 has been reported previ-
ously in several models of pathological
ventricular hypertrophy/remodeling and
HF (9,15–18). However, little is known
regarding the influence of DIO3 expres-
sion in the diabetic heart. We hypothe-
sized that the reduction in myocardial
TH levels observed in diabetic hearts is
the result of DIO3-mediated TH degra-
dation. We observed a significant in-
crease in DIO3 protein expression and a
tendency for increased tissue DIO3
mRNA expression in diabetic hearts (see
Figure 5) (18,44). In agreement with pre-
vious findings (15), we observed a het-
erogeneous DIO3 staining pattern
throughout the myocardium with the
vast majority of staining localized to car-
diomyocytes. T3 treatment normalized
DIO3 protein content in the tissue with a
concomitant reduction in expression of
DIO3 mRNA. Since DIO3 has been
shown to be HIF-responsive (18), the cor-
relation of changes in DIO3 expression,
arteriolar vessel density and other re-
ported parameters, suggest reversal of
tissue hypoxia as a plausible mechanistic
link between low-dose T3 treatment and
correction of tissue T3 levels.
In addition to myocardial inactivation
of THs, TH bioavailability within cardiac
tissue is crucial to normal TH homeosta-
sis. Although TH transport is a highly
regulated process (45–48), TH transporter
expression has not been explored in great
depth in the heart. Therefore, we investi-
gated the relationship between tissue TH
status and the gene expression profile of
TH transporters. We observed a general
pattern of increased TH transporters
within the untreated STZ/N group,
which was normalized with TH treat-
ment (see Figure 6). Of note, this expres-
sion pattern was not observed in one of
the most important TH transporters,
MCT-10. It is well established that MCT-8
and MCT-10 are the major TH trans-
porters, and MCT-10 is arguably more
active than MCT-8 (46). Interestingly, a
similar expression pattern (increased
MCT-8 and decreased MCT-10) has been
reported in muscle from patients with
prolonged critical illness with depressed
serum TH levels and increased rT3 (pos-
sibly due to DIO3 induction). However,
this expression pattern was not consis-
tent in all organs or phases of critical ill-
ness (acute versus prolonged) (45). In the
current study, attenuation of the decline
in tissue THs by T3 treatment appeared
to completely normalize MCT-10 expres-
sion while the expression of MCT-8 was
further increased with T3. This observa-
tion, along with greater than a two-fold
higher basal level of expression (see Fig-
ure 6), suggests that MCT-10 may play a
crucial role in tissue TH bioavailability in
the diabetic heart.
Due to its beneficial regulation of key
Ca2+ handling proteins, myosin isoforms
and antifibrotic activity, T3 represents an
attractive adjunct therapy to improve re-
laxation/diastolic function, and prevent
disease progression in the diabetic heart
(7,8,49,50). LV stiffness, relaxation abnor-
malities and diastolic dysfunction are
recognized as early and widespread pre-
clinical manifestations of DM-related car-
diac dysfunction and generally occur be-
fore the onset of severe systolic
impairment (3,51,52). Abnormal Ca2+
handling is a cardinal feature of diabetic
dysfunction and plays a causal role in re-
laxation abnormalities, diastolic dysfunc-
tion and fibrotic accumulation (3,28,29).
Diabetic hearts are known to have in-
creased dysfunction of Ca2+ regulatory
proteins (for example, SERCA2a) and ex-
perimental normalization of calcium
Figure 5. LV Deiodinase Expression. (A) LV DIO3 staining in control and diabetic hearts at
2× magnification. (B) DIO3 IHC protein quantification. Values represented as the percent-
age of DIO3 staining versus the total tissue area. (C) DIO2, type 2 deiodinase mRNA ex-
pression. (D) DIO3, type 3 deiodinase mRNA expression. Gene expression values repre-
sented as means (SD). Gene expression was normalized using the housekeeping genes
cyclophilin A and Rplp1; n = 3-5/group. *p < 0.05 versus control; †p < 0.05 versus STZ/N.
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handling by the overexpression of key
regulatory proteins (for example,
SERCA2a) has been shown to improve
myocardial function in diabetic car-
diomyopathy (29). THs are known to
augment myocardial relaxation and pre-
vent calcium overload by stimulating the
expression and activity of key Ca2+ regu-
lators (for example, SERCA2a, Na+/Ca2+
exchanger, RYR2), while inhibiting the
activity of PLB (7,8,13,30,31,53) and the
opposite is true during hypothyroidism.
In the current study, tissue hypothy-
roidism caused by STZ/N led to signifi-
cant diastolic abnormalities and de-
creased expression of important Ca2+
handling genes. T3 replacement signifi-
cantly improved functional parameters
of diastolic function (tau, and dP/dT
Min) (see Figure 2) and normalized the
expression of SERCA2a, RyR2, and α/β-
MHC (Figure 4 and Supplementary Fig-
ure 5). Interestingly, the dysfunction ob-
served in the STZ/N group occurred be-
fore the onset of appreciable LV fibrosis
(Supplementary Figure 7) and suggests
that other abnormalities (for example,
Ca2+ handling, blood flow, increased car-
diomyocyte resting tension) are responsi-
ble for this early dysfunction. Our data
indicate that detection of diastolic dys-
function before the occurrence of signifi-
cant LV remodeling/hypertrophy, LV
collagen accumulation and severe sys-
tolic impairment is critically important
and represents a promising therapeutic
window for T3 replacement therapy.
Finally, we examined the effect of T3 re-
placement on the cardiac microvessel net-
work in diabetic hearts since THs have
been shown to be important proangio-
genic regulators of the cardiac vascular
network and influence vasoreactivity and
blood flow mechanisms (7,14,27,34,54).
We have previously shown that hypothy-
roidism caused by thyroidectomy leads
to significant reductions in arteriolar
length density and that TH treatment
leads to robust proliferation of endothe-
lial cells, pericytes, vascular smooth mus-
cle cells and normalization of arteriolar
LD (34,42). Moreover, we have reported
that experimental hypothyroidism leads
to arteriolar resistance vessel remodeling
and impaired resting and maximum
blood flow in a manner dependent on the
duration of hypothyroidism (13). It is
well established that diabetic hearts are at
an increased risk for both macro- and mi-
crovascular pathology and although
many factors likely contribute to diabetic
vascular dysfunction (for example, hy-
perglycemia, reactive oxygen species),
low cardiac tissue TH levels may con-
tribute to or exacerbate microvascular
dysfunction in diabetic hearts. Cardiac
microvessel remodeling, endothelial dys-
function, increased arteriolar tone/va-
soreactivity, decreased vascular growth
factor expression, impaired myocardial
blood flow and diminished blood flow
reserve are common features of both DM
and overt/subclinical hypothyroidism
(4,13,25–27,54–56).
In the current study, DM was associ-
ated with reductions in both number and
density (~25%) of small arteriole resist-
ance vessels (Figure 3). In addition, un-
treated diabetic hearts had significantly
reduced gene expression of key vascular
regulators (TR-β, VEGF-A, eNOS) (see
Figure 3) and a trend for reduced bFGF
gene expression. It is not surprising that
diminished expression of these impor-
tant vascular regulators would lead to
vascular remodeling, considering that
aberrant expression or knockout models
of these regulators exhibit severe mi-
crovascular impairment and abnormal
angiogenesis (4,57–59). Interestingly, dia-
betic hearts had significant upregulation
of the heparin-binding growth factor
MdK, which has been shown to be nega-
tively regulated by THs and is increased
during experimental hypothyroidism
(34). Increased MdK levels also have
been shown to be a predictor of cardiac
events and deteriorating cardiac function
in patients with chronic heart failure (60).
Figure 6. Expression of cardiac thyroid hormone transporters. Gene expression values rep-
resented as means (SD). Gene expression was normalized using the housekeeping genes
cyclophilin A and Rplp1. (A) MCT, monocarboxylate transporters; LAT, large neutral amino
acid transporters. (B) 4F2hc, 4F2 cell surface antigen heavy chain; FAT, fatty acid translo-
case; SLCO, solute carrier organic anion transporter family. n = 5/group; *p < 0.05 versus
control; †p < 0.05 versus STZ/N.
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T3-treated diabetic hearts showed
preservation of small arteriole resistance
vessels, with attenuation of the decline in
vascular gene expression (see Figure 3).
The beneficial effects of T3 treatment also
may be due to preservation of coronary
perfusion (preserved SBP and LV hemo-
dynamics) or by direct regulation of
ECs, pericytes and VSMCS. Our findings
are consistent with reports noting that
reversing cardiac hypothyroidism by
THs or their analogues can preserve the
small arteriole resistance vessel network
(14,34,42,56,57). Moreover, we have pre-
viously shown that the TH analogue
DITPA (3,5-diiodothyropropionic acid)
can prevent arteriolar loss in hypothy-
roid rodents independent of cardiac
function (61). The above findings sug-
gest that the combined influence of THs
on arteriolar vascular tone and density
and the preserved gene expression of
vascular regulators are likely to reverse
the increased coronary vascular resist-
ance and to improve blood flow in dia-
betic hearts.
Despite this early arteriolar remodel-
ing, no differences were observed in cap-
illary density or total capillary length
among control or diabetic groups (see
Figure 3), suggesting that arteriolar re-
modeling and potential blood flow ab-
normalities occur before the onset of cap-
illary rarefaction. It has been reported
that capillary rarefaction is not present
during the early evolution of DM-
 induced cardiac dysfunction and occurs
later in disease progression (4). It is not
surprising that we did not observe
changes in capillary density, considering
that there were no notable signs of my-
ocyte hypertrophy, myocardial degenera-
tion or replacement fibrosis at this early
stage.
Our study has several limitations.
First, due to the high tissue requirement
for tissue TH quantitation method
(~350–500 mg), LV samples from ani-
mals within the same treatment groups
were pooled together. Unfortunately,
this does not allow for individual corre-
lation between TH status (serum and
tissue) and cardiac function, thus limit-
ing statistical power. Second, although
extensive morphological characteriza-
tion of the cardiac microvasculature was
undertaken, we did not measure coro-
nary blood flow. Thus, we cannot defin-
itively conclude that arteriolar remodel-
ing and tissue hypothyroidism led to
impaired coronary flow in this study.
However, numerous previous reports
have confirmed that coronary flow is
impaired by diabetes, low TH conditions
and/or arteriolar remodeling and is aug-
mented by or preserved with thyroid
hormone treatment (4,13,25–27,54–56).
Third, we were unable to find reliable
commercial antibodies needed to con-
firm protein expression changes for the
reported TH transporters, cytosolic
binding proteins. Finally, due to limited
resources and tissue availability, we
were unable to measure DIO3 enzy-
matic activity to confirm increased tis-
sue DIO3 protein content.
CONCLUSION
This study shows that chronic DM,
without superimposed pathological car-
diac stimuli, led to cardiac tissue hy-
pothyroidism despite normal serum TH
levels, potentially as a result of increased
myocardial DIO3 activity. Low-dose re-
placement with T3 restored cardiac tis-
sue TH levels, attenuated cardiac dys-
function, improved cardiac relaxation,
reversed fetal gene expression and pre-
served the arteriolar resistance vessel
network without causing overt symp-
toms of hyperthyroidism. T3 replace-
ment therapy appears to be an effective
adjunct therapy to attenuate and/or re-
verse adverse cardiac remodeling and
dysfunction induced by experimental
DM. In previous experiments, we noted
that excessive doses of T4 (42) or T3 (35)
were needed to restore cardiac tissue T3
levels and LV function in rats with pri-
mary hypothyroidism. The results of the
current experiment are exciting since a
low, therapeutic dose of T3 led to dra-
matic cardiac improvements. This sug-
gests that cardiac tissue hypothyroidism
secondary to heart diseases, can be re-
stored safely. Other ongoing animal ex-
periments in our lab suggest this may
also be true for other heart diseases
leading to HF. Finally, it will be exciting
to investigate whether physiologic T3
treatment is beneficial in type 2 DM, a
global crisis desperately in need of new
treatment options.
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